SGP SpyGlass Pharma, Inc. Common Stock
HealthcareAs of 2026-05-25
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
1.66
P/S
0.00
EV/EBITDA
-16.12
DCF Value
$2.77
FCF Yield
-3.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-123.5%
ROA
-10.2%
ROIC
-11.5%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 null | $0.00 | $-13.8M | $— |
| Q4 null | $0.00 | $-12.6M | $— |
| FY null | $0.00 | $-39.9M | $— |
Analyst Ratings
View AllConsensus
Buy
Target (Consensus)
$62.00
Target (Median)
$62.00
Target Range
$62.00 - $62.00
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.00
SpyGlass Pharma, Inc. is a late-stage biopharmaceutical, which engages in the development of treatment paradigm for patients living with chronic eye conditions. Its lead product candidate, Bimatoprost Drug Pad-IOL System (BIM-IOL System), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) for patients who have wither open-angel glaucoma (OAG) or ocular hypertension (OHT). The company was founded in January 2019 by Malik Y. Kahook and Glenn Sussman and is headquartered in Aliso Viejo, CA.